✦ LIBER ✦

Overview of the Safety of Felodipine Based on Clinical Trials in Patients With Hypertension

✍ Scribed by Lennart Welin; MD; PhD; Lars Elvelin; DDS; Anne Niklasson; RN; Gunnar Olsson; MD; PhD; Dag Elmfeldt; MD; PhD

Book ID: 113978226
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 171 KB
Volume: 79
Category: Article
ISSN: 0002-9149
DOI: 10.1016/s0002-9149(97)00034-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Control of hypertension in elderly patie

Control of hypertension in elderly patients with felodipine and metoprolol: a double-blind, placebo-controlled clinical trial.

✍ P Freeling; RH Davis; JR Goves; RH Burton; EA Orme-Smith 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 677 KB

Effect of felodipine on the serum lipid

Effect of felodipine on the serum lipid profile of patients with hypertension

✍ Maninder Kaur; Kiranjeet Kaur; Gurdeep Kaur Bedi; Gurpreet Singh Sidhu; Roopan S 📂 Article 📅 2000 🏛 Association of Clinical Biochemistry of India 🌐 English ⚖ 340 KB

Overview of the outcome trials in older

Overview of the outcome trials in older patients with isolated systolic hypertension

✍ Staessen, J A; Wang, J G; Thijs, L; Fagard, R 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 121 KB

An overview of the safety and efficacy o

An overview of the safety and efficacy of nicardipine in clinical trials

✍ Karl Agre 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 504 KB

Randomised clinical trial: the safety an

Randomised clinical trial: the safety and efficacy of long-acting octreotide in patients with portal hypertension

✍ N. Chandok; P. S. Kamath; A. Blei; J. Bosch; W. Carey; N. Grace; K. V. Kowdley; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB

Adalimumab safety in global clinical tri

Adalimumab safety in global clinical trials of patients with Crohn's disease

✍ Jean-Frédéric Colombel; William J. Sandborn; Remo Panaccione; Anne M. Robinson; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 2 views

Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr